Overview

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Phase:

Phase 2

Details

Lead Sponsor:

Ophthotech Corporation

Treatments:

Ranibizumab